Merck (MRK) Payables (2009 - 2026)
Merck (MRK) reported Payables of $6.0 billion for Q1 2026, up 2.47% year-over-year from $5.9 billion in Q1 2025, and down 8.22% quarter-over-quarter from $6.5 billion in Q4 2025.
Merck (MRK) Payables (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Payables data on file, last reported at $6.0 billion in Q1 2026.
- Payables for Q1 2026 came in at $6.0 billion, up 2.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.0 billion (up 2.47% YoY), and the FY2025 annual result was $6.5 billion, up 6.18% from the prior year.
- Payables fell to $6.0 billion in Q1 2026 per MRK's latest filing, from $6.5 billion in the prior quarter.
- Over five years, Payables peaked at $6.5 billion in Q4 2025 and troughed at $5.1 billion in Q3 2022.
- A 5-year average of $5.7 billion and a median of $5.6 billion in 2023 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2025: Payables dropped 5.56% in 2022, then gained 11.15% in 2025.
- A 5-year view of Payables shows it stood at $6.1 billion in 2022, then retreated by 3.92% to $5.9 billion in 2023, then rose by 4.33% to $6.2 billion in 2024, then climbed by 6.18% to $6.5 billion in 2025, then slipped by 8.22% to $6.0 billion in 2026.
- Business Quant data shows MRK's Payables at $6.0 billion in Q1 2026, $6.5 billion in Q4 2025, and $6.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -26.13 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 5.03 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 27.92 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 33.77 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 6.01 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 4.23 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.01 Bn |
| Dec 31, 2025 | 6.54 Bn |
| Sep 30, 2025 | 6.19 Bn |
| Jun 30, 2025 | 5.95 Bn |
| Mar 31, 2025 | 5.86 Bn |
| Dec 31, 2024 | 6.16 Bn |
| Sep 30, 2024 | 5.57 Bn |
| Jun 30, 2024 | 5.50 Bn |
| Mar 31, 2024 | 5.52 Bn |
| Dec 31, 2023 | 5.91 Bn |
| Sep 30, 2023 | 5.39 Bn |
| Jun 30, 2023 | 5.32 Bn |
| Mar 31, 2023 | 5.59 Bn |
| Dec 31, 2022 | 6.15 Bn |
| Sep 30, 2022 | 5.14 Bn |
| Jun 30, 2022 | 5.25 Bn |
| Mar 31, 2022 | 5.49 Bn |
| Dec 31, 2021 | 6.38 Bn |
| Sep 30, 2021 | 5.03 Bn |
| Jun 30, 2021 | 5.56 Bn |